Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lisata Therapeutics Inc LSTA

Healthcare Biotechnology
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to... see more

Recent & Breaking News (NDAQ:LSTA)

Caladrius Biosciences Subsidiary, PCT, Earns FACT Re-Accreditation for its Cell Therapy Development and Manufacturing Facilities

GlobeNewswire November 22, 2016

Caladrius Biosciences Reports 2016 Third Quarter Financial Results

GlobeNewswire November 7, 2016

Caladrius Biosciences to Host 2016 Third Quarter Financial Results Conference Call on November 7 at 5:00 pm Eastern Time

GlobeNewswire November 2, 2016

Caladrius Biosciences Begins Enrollment of Second Cohort of Phase 2 Trial of CLBS03 as a Treatment for Type 1 Diabetes Following Favorable Safety Data from First Cohort

GlobeNewswire October 31, 2016

Caladrius Biosciences to Present at Upcoming November Conferences

GlobeNewswire October 27, 2016

Caladrius Biosciences Appoints Gregory R. Brown, MD, to its Board of Directors

GlobeNewswire October 12, 2016

Caladrius Biosciences, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia

Accesswire October 11, 2016

Caladrius Biosciences to Present at Upcoming October Conferences

GlobeNewswire October 4, 2016

Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization

GlobeNewswire September 19, 2016

Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement with Adaptimmune

GlobeNewswire September 19, 2016

Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in Common Equity Priced At Market Without Warrants

GlobeNewswire September 15, 2016

Caladrius Biosciences to Present at Upcoming September Conferences

GlobeNewswire September 8, 2016

Caladrius Biosciences Completes Enrollment of First Patient Cohort in Phase 2 Trial of CLBS03 to Treat Type 1 Diabetes

GlobeNewswire September 6, 2016

Caladrius Biosciences Reports 2016 Second Quarter Financial Results

GlobeNewswire August 9, 2016

Caladrius Biosciences to Host 2016 Second Quarter Financial Results Conference Call on August 9 at 5:00 pm Eastern Time

GlobeNewswire August 2, 2016

Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes

GlobeNewswire July 28, 2016

Caladrius Biosciences Announces 1-for-10 Reverse Split

GlobeNewswire July 27, 2016

Caladrius Biosciences to Present at Upcoming July Conferences

GlobeNewswire July 7, 2016

Caladrius Biosciences SVP and President of PCT, Robert Preti, PhD, Named Chairman of the Alliance for Regenerative Medicine

GlobeNewswire June 27, 2016

Rockwell Medical Announces Appointment of Dr. Robin Smith to Board of Directors

GlobeNewswire June 23, 2016